Event-Driven Stocks

Poseida Therapeutics, Inc.

PSTX

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 4 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY23FY22FY21FY20FY19
Revenue$64.7M$130.5M$31.2M——
Operating income−$129.5M−$59.9M−$141.4M−$126.5M−$85.5M
Net income−$123.4M−$64.0M−$125.0M−$129.8M−$86.5M
Total assets$273.9M$351.8M$269.3M$371.5M$147.0M
Total liabilities$170.2M$164.2M$113.1M$109.5M$74.3M
Equity$103.7M$187.6M$156.2M$262.0M−$149.5M
EPS (diluted)$-1.37$-0.89$-2.01——
Shares out.86.5M62.5M62.1M61.9M13.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2023
Operating margin
−200.2%
Net margin
−190.8%
Return on equity
−119.0%
Return on assets
−45.1%
Return on capital (ROCE)
−63.9%
Liabilities / assets
62.1%
Debt / equity
1.64×
Book value / share
$1.20
Revenue growth (YoY)
−50.4%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2023
Altman Z″ (distress)
-5.90distress
Accruals / assets
−11.4%clean
Piotroski F-Score
1/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
30
/ 100
Profitability 0Growth 0Catalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 4 warning● 1 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)